NASDAQ · XFOR
X4 Pharmaceuticals, Inc.
$3.35-$0.01 (-0.3%)
X4 Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 30.64% below the high.
Loading market information…
NASDAQ · JUNS · USD
Stock price, earnings
Quote as of Oct 30, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Jupiter Neurosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.13% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Jupiter Neurosciences, Inc.’s next earnings report is currently expected on Dec 2, 2026, with estimated earnings per share of -$3.75. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Jupiter Neurosciences, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Jupiter Neurosciences, Inc. is a pharmaceutical company engaged in clinical-stage research and development. Its primary focus is on advancing a resveratrol-based platform product, with the main objective of addressing neuro-inflammation. The company's pipeline includes several drug candidates: JNS101 is undergoing Phase II trials for Friedreich's Ataxia, a rare neurological disorder that damages the nervous system and causes mobility issues. Also in Phase II, JNS102 is being developed for mucopolysaccharidosis Type I, JNS107 for MELAS Syndrome, and JNS108 for mild cognitive impairment and early Alzheimer's disease. Furthermore, the company is progressing JNS109 for amyotrophic lateral sclerosis, JNS110 for traumatic brain injury and concussion, and JNS120 as a treatment for COVID-19. Founded in 2016, the company, formerly known as Jupiter Orphan Therapeutics, Inc., adopted its current name in August 2021 and is headquartered in Jupiter, Florida.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:04 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 15, 2025 | -$3.76-66.37% vs estimate | $0.00 |
|---|
| Q4 2024 | Mar 28, 2025 | -$3.76-150.67% vs estimate | $0.00 |
|---|
| Q3 2024 | Dec 23, 2024 | -$1.50 | $0.00 |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.35-$0.01 (-0.3%)
X4 Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 30.64% below the high.
$29.08$0.00 (0.0%)
Mersana Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.31% below the high.
$7.29$0.00 (0.0%)
Kezar Life Sciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.44% below the high.
$9.07-$0.15 (-1.63%)
FibroGen, Inc.’s quoted price sits in the lower half of its reported 52-week range, 58.68% below the high.
$1.94$0.00 (0.0%)
Grace Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.55% below the high.
$4.80-$0.23 (-4.57%)
Aligos Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 64.94% below the high.
$1.94+$0.05 (+2.65%)
Serina Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.2% below the high.
$1.00-$0.04 (-3.85%)
ABVC BioPharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.32% below the high.
